BananaIP Counsels Logo

Celebrating 20 Years of IP Excellence

CL x

Compulsory Licensing in India – Talk by Gaurav Mishra

Mr. Gaurav Mishra, Managing Associate at BananaIP Counsels delivered a talk on the Compulsory licensing provisions in India under the Patents Act on the 3rd of June 2020 at an event organized by the Department of Science and technology, Rajasthan. The webinar event was attended by over a 100 participants including, students, lawyers, medical professionals and academicians.  The talk was delivered as part of the Rajasthan, DST's laudable initiative of creating IP awareness as well as helping the attendees grasp…
June 3, 2020 Intellectual Property, Patents 0Comment 893Views 0Like
Share

Read more

The featured image shows the words thats all folks. this post is about the decision of two indian generic drug manufactures to drop their request for Compulsory licenses. to read more click here.

Lee and BDR decision – the End of Compulsory Licenses?!

Earlier this week, the words, “Compulsory License”, “Section 84” and “Indian pharma” once again made the headlines. This time however, it wasn’t a new case being brought forth; instead it was the decision to bury two old ones. The news reports suggested that two Indian drugmakers had given up a battle to copy drugs developed by Bristol Myers Squibb and AstraZeneca, blaming a lack of government support for cheap generics and pressure from Big Pharma. The two Indian drug makers…
April 16, 2016 Intellectual Property, Patents 0Comment 865Views 0Like
Share

Read more

Medicines pharma x

Lee Pharma v. AstraZeneca- An unfinished Patent Story

Compulsory licensing cases and India have a peculiar relationship. They are in a way, soul sisters in the world of Intellectual property. Section 84 of the Patents Act, 1970 has always been the subject of intense debate. It hasn’t been very long since India issued its first ever compulsory licence to Natco Pharma, an Indian generic company, for Bayer’s blockbuster anti-cancer drug Nexavar (Sorafenib) in March 2012. Two other CL applications followed the Nexavar case, one relating to Roche’s Herceptin…
September 4, 2015 Intellectual Property, Patents 0Comment 2711Views 0Like
Share

Read more